Three Classic Defensive Dividend Stocks — Only Two Actually Pass the Safety Test

The 10-year Treasury is yielding above 4.5%. The 30-year crossed 5% in May and surged again after the Federal Reserve's late-July meeting. That is the real competition for dividend stocks right now, not some abstract notion of market volatility. When the risk-free alternative pays that much, every dividend name needs to earn its place in the portfolio. "Low risk" is a lazy label until you test the income engine.

I looked at three of the most commonly recommended defensive dividend stocks — Procter & Gamble, Johnson & Johnson, and Colgate-Palmolive. All three carry long streaks of consecutive dividend increases and sell products people buy regardless of the economy. But only two of them actually pass the cash-flow safety test at these terms.

Procter & Gamble: The best income entry of the three

P&G trades at about $146, down roughly 9% over the past four months. That price drop is the useful part of this story, because the cash-flow engine has not broken.

The stock yields about 2.95% on a trailing basis, with 22 consecutive years of dividend increases. The payout ratio sits at roughly 59% of earnings, and free cash flow over the trailing twelve months came in at $15.15 billion, growing nearly 8% year over year. That is $15.15 billion of cash after capital expenditures, funding a dividend of roughly $4.30 per share annually. The dividend is covered about 3.5 times by free cash flow.

P&G raised its quarterly dividend to $1.0885 per share in April 2026, and its fiscal year ending June 2026 showed net sales up 3% with organic growth of 1%. Growth is slow, but the question for an income portfolio is whether the engine keeps running, not whether it accelerates. It does.

The balance sheet is manageable: $72.2 billion in total debt against $9.9 billion in cash, for net debt of $24.2 billion and a debt-to-equity ratio of 63%. The stock trades at about 21 times trailing earnings and 15.8 times EV/EBITDA, the lowest multiple of the three names here.

If the income stream is still sound, a 9% drawdown over four months means you can buy more future income on better terms. P&G is the name where the current price actually helps the income investor.

Johnson & Johnson: The overhang just lifted, but the stock already reflected it

J&J announced on July 27 that it will pay $5.5 billion to resolve tens of thousands of remaining lawsuits alleging its talc products cause ovarian cancer. The settlement removes a decade of litigation uncertainty that has sat on the balance sheet like an un-priced option held by plaintiffs.

The cash-flow numbers look exceptional. Free cash flow over the trailing twelve months came in at $22.61 billion, up 24% year over year. The dividend yield is 2.02%, the payout ratio is about 60%, and J&J has 23 consecutive years of dividend increases. Earnings have beaten consensus estimates in each of the last two reported quarters.

The forward picture supports the dividend too. The stock trades at a trailing PE of nearly 30, but the forward PE is just 18.9. That gap reflects the one-time drag of the talc settlement flowing through trailing earnings while the forward view assumes a clean slate. Consensus EPS for the next two quarters sits at $2.76 and $2.85, respectively, both above what the stock earned in recent quarters.

Here's the catch: the stock is up 25% year-to-date and nearly 50% on a rolling annual basis. It's trading around $259, close to its 52-week high of $275. The market has already rewarded the resolution. A 2% yield against a Treasury paying 4.5% means you're paying up for the clarity, not collecting a competitive income rate right now.

The dividend is safe — the question is whether you can afford the premium.

Colgate-Palmolive: The "safe" name that looks stretched

Colgate is the one that doesn't pass the safety test, and the problem isn't the business — it's the balance sheet.

Colgate-Palmolive controls roughly 41% of the U.S. toothpaste market and has raised its dividend for 23 consecutive years. Its free cash flow grew 14.5% year over year to $3.86 billion, and earnings have consistently beaten consensus estimates. The business itself is steady.

But look at the equity base: $566 million. Total debt is $16.2 billion. That gives a debt-to-equity ratio of 1,388% — the equivalent of borrowing $1,388 for every dollar of shareholder equity. This isn't a leverage problem in the traditional sense; it's the result of years of aggressive share buybacks. Colgate authorized a $5 billion buyback program in March 2025 and has been a consistent repurchaser. The company has been shrinking the equity base while paying out more in dividends.

The payout ratio of 80% of earnings reinforces the concern. At that level, there's little cushion for the dividend if earnings even briefly miss. The trailing PE of 36.5 is the highest of the three names, and the EV/EBITDA multiple of 21.4 sits above P&G's 15.8 and J&J's 19.2.

Colgate is not a broken business. But a dividend that takes 80% of earnings, backed by a $566 million equity base and priced at 36 times trailing earnings, is not the "low risk" anchor the headline implies. If the income engine stutters, there's no margin for error.

What the income investor actually does with this

The 10-year Treasury paying above 4.5% is the benchmark these stocks need to clear. You own dividend names not because they're vaguely "defensive" but because the income stream is durable enough to fund a retirement portfolio without forcing you to sell pieces at the wrong time.

P&G clears that test at the current price. The 2.95% yield isn't a Treasury match, but the payout is covered by real free cash flow growth, the multiple is the most reasonable of the group, and the recent price weakness offers better entry terms. This is the name where volatility feeds reinvestment logic.

J&J is durable but expensive. The talc settlement removes a real overhang, and the forward earnings profile supports the dividend. But at a 2% yield and a 25% year-to-date gain, you're buying safety at a premium. It belongs in the portfolio as a core holding, not as a fresh entry.

Colgate looks safe on the label but not on the plumbing. An 80% payout ratio and a $566 million equity base are not the structural foundations you want when bond yields are elevated and the opportunity cost of owning expensive dividend stocks is real. It's the one that needs to be sold first if you're trimming.

The bond market is offering yields that force a conversation about every dividend holding. The right answer isn't to run from stocks or to blindly hug the usual defensive names. It's to inspect the cash-flow engine, check the terms, and own the income streams that actually cover what they promise.